This article was originally published in The Gray Sheet
Roughly 100 state and federally funded laboratories have received experimental polymerase chain reaction test technology from the Centers for Disease Control & Prevention for severe acute respiratory syndrome as of June 2, CDC says. Informed consent will be required of patients using the PCR diagnostic and information from the labs will be collected by the agency. Developed by CDC over the past few months, the test was made available a week after HHS officials met with in vitro test makers to discuss how to expedite SARS diagnostic development (1"The Gray Sheet" June 2, 2003, p. 22)...
You may also be interested in...
The investigational device exemption process for diagnostic tests related to disease outbreaks should be expedited, FDA acknowledges
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.